Bullish case
$64 to $70
More likely if AUSTEDO, AJOVY, UZEDY, biosimilars, and late-stage assets outperform; margins approach management targets; free cash flow reduces leverage; and investors sustain a high-teens earnings multiple.
Teva Pharmaceutical Industries Limited research snapshot
TEVA AI Stock Analysis
TEVA AI stock analysis currently reads Teva Pharmaceutical Industries as a global generics and specialty medicines company whose innovative portfolio is improving the earnings mix. At the July 8, 2026 data cutoff, TEVA closed near $33.04 with an implied market capitalization of about $38.71 billion. AUSTEDO, AJOVY, UZEDY, biosimilars, margin improvement, and debt reduction support the recovery case. Generic pricing pressure, pipeline and regulatory outcomes, acquisition integration, and $16.9 billion of total debt remain material constraints. This page is informational research, not investment advice.
Current price
$33.04 close
Market cap
$38.71 billion
AI score
68 / 100
Rating
Improving pharma turnaround with leverage and execution risk
Trend status
Constructive long-term trend above the 50-day and 200-day moving averages after a sharp run
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- A-level information richness. Teva has detailed earnings releases, public filings, long financial history, liquid market data, broad analyst coverage, and multiple independent financial-data providers.
- bias Check
- The main AI bias risk is extrapolating the recent share-price recovery and innovative-product growth while under-weighting generics price pressure, debt, clinical and regulatory risk, legal charges, foreign exchange, and the difference between GAAP and non-GAAP earnings.
- ai Confidence
- High for FY2025 revenue and net income, Q1 2026 reported results, cash, debt, shares, market-cap math, guidance, and moving-average data. Medium for forward valuation because product growth, generic competition, deal costs, and market multiples can change quickly.
- investment Certainty
- Medium. The improving portfolio mix and cash-flow outlook are measurable, but the investment case still depends on execution, deleveraging, and durable innovative-product growth.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Teva sells generic medicines, biosimilars, specialty medicines, APIs, and distribution services across the United States, Europe, and international markets. | Medium-high |
| Moat | Scale manufacturing, regulatory know-how, broad distribution, complex-product capabilities, and established prescriber access matter, but generic products face persistent price competition. | Medium |
| Management | President and CEO Richard Francis is executing the Pivot to Growth plan. The capital-allocation test is whether innovation, cost savings, acquisitions, and debt reduction create durable cash returns. | Medium |
| Financial trend | FY2025 revenue was $17.258 billion and GAAP net income was $1.410 billion. Q1 2026 revenue was about $4.0 billion and GAAP diluted EPS was $0.31. | High |
| Valuation | At $33.04, audited TTM inputs imply about 24.66x GAAP EPS, 4.69x book value, and 33.04x free cash flow per share. The forward non-GAAP multiple is lower but depends on guidance delivery. | Medium-high |
| Technical trend | The July 8 snapshot showed price below the 50-day average near $34.00 but above the 200-day average near $29.40. RSI near 55.73 was neutral rather than extreme. | Medium |
| Risk level | Risks include generic price erosion, debt, interest expense, product concentration, FDA and EMA decisions, litigation, supply disruption, foreign exchange, and acquisition execution. | Medium-high |
| AI confidence | Reported data and arithmetic have high confidence. Exact return forecasts have lower confidence because drug, earnings, and regulatory events can reprice TEVA quickly. | High data confidence |
| Investment certainty | Medium certainty. The recovery has evidence, but the valuation already assumes meaningful execution and does not remove the balance-sheet or portfolio risks. | Medium |
TEVA AI stock forecast
TEVA AI Stock Forecast Scenarios
The TEVA AI stock forecast uses audited scenario math around the $33.04 July 8 quote and the midpoint of Teva’s $2.57 to $2.77 stand-alone 2026 non-GAAP EPS outlook. The three-year framework produces a bearish area near $37, a base area near $52, and a bullish area near $68 before dividends. These are scenarios, not price targets.
Base case
$49 to $55
More likely if Teva meets 2026 revenue, EBITDA, EPS, and free-cash-flow guidance while innovative growth offsets generic pressure and the market applies a mid-teens multiple.
Bearish case
$34 to $39
More likely if generic price erosion, FX, acquisition costs, debt service, weak launches, regulatory setbacks, or pipeline disappointments keep earnings growth close to 2% and the multiple near 13x.
TEVA AI technical analysis
TEVA AI Technical Analysis
TEVA AI technical analysis is mixed but still constructive on the July 8, 2026 cutoff. StockAnalysis listed a $33.04 close, a 50-day moving average near $34.00, a 200-day moving average near $29.40, RSI near 55.73, and average 20-day volume near 5.69 million shares. SwingTradeBot listed support at $32.49, $31.74, and $30.90 and resistance at $34.08, $34.92, and $35.67.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $33.04 | StockAnalysis close on July 8, 2026, used for market-cap and valuation math. |
| Near support | $32.49 to $31.74 | SwingTradeBot listed these as nearby support levels at the data cutoff. |
| Secondary support | $30.90 to $29.40 | The lower listed support and the 200-day moving average form a deeper support zone. |
| Near resistance | $34.08 to $35.67 | The 50-day average and listed resistance levels must be reclaimed for a stronger short-term trend. |
| 50-day moving average | $34.00 | Price was just below this average on the July 8 snapshot. |
| 200-day moving average | $29.40 | Price remained above the long-term moving average, supporting the larger recovery trend. |
| Momentum | RSI 55.73 | Momentum was positive to neutral, not a stand-alone buy signal. |
| Volume | 20-day average 5.69 million shares | Watch volume around earnings, drug data, regulatory decisions, and debt updates. |
| Volatility | 52-week range $14.99 to $37.35 | The wide range shows that healthcare and execution news can cause large moves despite a beta near 0.86. |
| Invalidation | Close below $30.90, then $29.40 | A break below the secondary support and 200-day average would weaken the recovery trend. |
TEVA AI trading strategy
TEVA AI Trading Strategy Framework
This TEVA AI trading strategy is a rules-based research framework, not personal advice. It connects price levels with reported revenue, innovative-product growth, generic pricing, guidance, free cash flow, debt, regulatory events, and portfolio-level risk limits.
Trend-following setup
Watch for TEVA to reclaim and hold the $34.00 to $35.67 range with volume while quarterly innovative-product growth, guidance, EBITDA, and free cash flow remain on track.
A close below $30.90, especially with lower guidance, weaker AUSTEDO or AJOVY growth, or a regulatory problem, should weaken the setup.
Mean-reversion setup
If TEVA pulls back toward $31.74 to $30.90 without a new fundamental break, compare the valuation with normalized non-GAAP EPS, free cash flow, debt maturity needs, and the durability of innovative-product growth.
Do not treat a lower price as sufficient evidence of value if generic pricing, leverage, pipeline, litigation, or cash conversion deteriorates.
Fundamental monitor
Track AUSTEDO, AJOVY, UZEDY, biosimilar launches, generic erosion, 2026 revenue and EPS outlook, adjusted EBITDA, free cash flow, gross debt, net debt, interest expense, FDA and EMA milestones, and Emalex integration.
Position sizing should account for pharmaceutical event risk and should not rely on AI or consensus forecasts as certainty.
Investment research summary
Four-master Research Compression
Business essence
Teva gets paid when pharmacies, hospitals, payers, and patients need reliable, regulated access to generic, biosimilar, specialty, and innovative medicines at global scale.
Moat
The moat rests on scale manufacturing, regulatory filings, complex-product know-how, supply reliability, global distribution, and prescriber and payer access. It is strongest in differentiated products and weaker in commoditized generics.
Munger risk inversion
The thesis fails if innovative products do not offset generic erosion, debt remains restrictive, legal or quality costs recur, a pipeline program fails, integration absorbs capital, or payer and regulator pressure compresses economics.
Management
Richard Francis and the board need to show that Pivot to Growth converts product growth and transformation savings into cash flow, deleveraging, and disciplined reinvestment rather than only adjusted earnings.
Industry trend
Demand for affordable medicines, biosimilars, and neuroscience treatments is a long-term tailwind. Offsets include price pressure, regulatory scrutiny, reimbursement rules, patent litigation, and manufacturing complexity.
Valuation and margin of safety
The forward non-GAAP multiple appears more moderate than trailing GAAP and cash-flow measures, but margin of safety depends on guidance delivery, debt reduction, and whether the improving mix proves durable.
Source-backed data
TEVA Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| TEVA quote reference | $33.04 close on July 8, 2026 | StockAnalysis market cap page | July 8, 2026 |
| Market capitalization verification | $38.71 billion reported and $38.72 billion calculated from $33.04 x 1.172 billion shares, a 0.03% variance | Pineify financial_rigor.py, StockAnalysis, and Teva Q1 2026 results | July 8, 2026 |
| FY2025 revenue | $17.258 billion, cross-checked with Teva FY2025 results and Macrotrends | Teva FY2025 results | July 8, 2026 |
| FY2025 GAAP net income | $1.410 billion, cross-checked with Teva FY2025 results and Macrotrends | Teva FY2025 results | July 8, 2026 |
| Q1 2026 operating results | About $4.0 billion revenue, $0.31 GAAP diluted EPS, $0.53 non-GAAP diluted EPS, and $188 million free cash flow | Teva Q1 2026 results | July 8, 2026 |
| 2026 outlook | $16.4 billion to $16.8 billion revenue, $4.23 billion to $4.53 billion adjusted EBITDA, $1.91 to $2.11 reported outlook EPS after Emalex effects, $2.57 to $2.77 stand-alone EPS, and $2.0 billion to $2.4 billion free cash flow | Teva Q1 2026 results | July 8, 2026 |
| Cash and debt | $3.741 billion cash and equivalents, $16.907 billion total debt, and negative $13.166 billion net cash at March 31, 2026 | Teva Q1 2026 results and StockAnalysis balance sheet | July 8, 2026 |
| Technical snapshot | 50-day average $34.00, 200-day average $29.40, RSI 55.73, and 20-day average volume 5.69 million shares | StockAnalysis statistics | July 8, 2026 |
Frequently Asked Questions
Read the VTRS AI stock analysisView BMY AI stock forecastExplore MRK AI technical analysisOpen Pineify AI Stock PickerBuild a rules-based trading strategyScreen stocks with Pineify
This TEVA AI stock analysis is an informational research tool only. It is not investment advice, not a recommendation to buy or sell Teva Pharmaceutical Industries Limited, and not a promise of future returns. Forecasts are scenario-based estimates from available public data and can be wrong.
Related Tools
Trading Strategy Builder
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Try it
Stock Screener
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Try it
AI Stock Picker & Screener
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
Try it